Rivaroxaban in non valvular atrial fibrillation: subgroups analysis

https://doi.org/10.4081/monaldi.2014.37

Authors

Abstract

After the ROCKET AF study main paper several subgroups analysis were recently published. These studies are useful to better evaluate the rivaroxaban efficacy and safety in different clinical conditions. Here the subgroup analysis of patients with moderate renal failure, heart failure and diabetes are presented. Post hoc data on patients who underwent an electrical or pharmacological cardioversion during ROKET AF follow up were available and here we analyze also the results of the first randomized study on electrical cardioversion in patients treated with new oral anticolagulants: the X-VeRT trial. A metanalysis of all the studies with rivaroxaban (one on stroke prevention in atrial fibrillation, two on acute coronary syndromes, four on deep venous thrombosis prophylaxis and two on pulmonary embolism treatment) with respect to the risk of myocardial infarction is examined.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Downloads

Published
2015-08-19
Info
Issue
Section
Reviews
Keywords:
Atrial fibrillation, new oral anticoagulants, rivaroxaban
Statistics
  • Abstract views: 964

  • PDF: 675
How to Cite
Greco, Cesare. 2015. “Rivaroxaban in Non Valvular Atrial Fibrillation: Subgroups Analysis”. Monaldi Archives for Chest Disease 82 (1). https://doi.org/10.4081/monaldi.2014.37.

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.